Key Highlights
- Novo Nordisk A/S CEO Mike Doustdar said the company is weighing a direct listing on the New York Stock Exchange.
- The comments came in an interview with the Financial Times, not a formal regulatory filing.
- The move is framed as an effort to boost Novo's US investor profile amid competitive pressure from Eli Lilly.
- Novo currently trades primarily on Nasdaq Copenhagen, with American depositary receipts already listed on the NYSE.
A CEO Signals Openness to a Direct Listing
Novo Nordisk A/S Chief Executive Mike Doustdar told the Financial Times the company is weighing a direct listing on the New York Stock Exchange, comments that came through a media interview rather than a formal filing, meaning the plan remains at an exploratory stage rather than a confirmed corporate action. A direct listing of this kind would supplement Novo's existing American depositary receipt program on the NYSE, potentially providing US investors with more direct access to the company's shares.
Competitive Pressure From Lilly as Context
The exploration of a direct listing is being framed as a move to boost Novo's profile among US investors at a moment when the company faces intensifying competitive pressure from Eli Lilly and Company (NYSE:LLY) in the GLP-1 obesity and diabetes drug market, where Lilly has been gaining significant market share, including within the Medicare segment. Strengthening its standing among US investors could help Novo access Capital and maintain visibility with the Market Segment most closely tracking developments in the fast-growing GLP-1 category.
Novo's Current Listing Structure
Novo Nordisk currently trades primarily on Nasdaq Copenhagen, its home market listing, with American depositary receipts already available on the NYSE providing US investors an existing avenue for exposure to the stock. A full direct listing would represent a more substantial step than the existing ADR structure, potentially offering greater Liquidity and more direct index inclusion possibilities for US-based investors and funds.
Where Things Stand
Novo Nordisk's exploration of an NYSE direct listing, disclosed through CEO Mike Doustdar's comments to the Financial Times, reflects the company's effort to strengthen its US investor profile as it competes intensely with Eli Lilly for share in the GLP-1 market. Whether this exploratory discussion advances into a formal listing plan will likely be closely watched by investors on both sides of the Atlantic.






Please wait processing your request...